The Future of Health

In this episode, Alex Rochegude, Cofounder of Predictiv, invited Dr. Jake Prigoff, Director of Research and Healthcare Lead at Gaingels - a diversity-focused investment group, to discuss about how technology is improving and changing our approach to diagnostics. Jake is a physician, survivor, and healthcare investor. After battling Stage 4 Lymphoma, Jake quickly moved toward the healthcare sphere as a speaker, advocate, and physician. He went to medical school at Mount Sinai in New York City and then followed that with training in General Surgery at Columbia University Medical Center. Jake has since left clinical medicine in pursuit of a broader impact on the healthcare system through the healthcare industry. --- Send in a voice message: https://podcasters.spotify.com/pod/show/thefutureofhealth/message

In this episode, Mhy-Lanie Adduru, Chief Medical Officer of Predictiv, invited Dr Steven Winiarski, Physician and Founder of Cholesterol Doctors, to discuss about how science and technology are changing our approach to diagnose and treat cholesterol. Dr Winiarski started the first telemedicine lipidology practice called Cholesterol Doctors, where he focuses on the treatment of challenging lipid disorders, statin intolerance, and performing advanced cardiovascular risk assessment. His special interest is leveraging 21st century tools and technology to optimize health and longevity, especially for those beyond middle age. --- Send in a voice message: https://podcasters.spotify.com/pod/show/thefutureofhealth/message

This month, we were celebrating the National Hispanic Heritage Month in the US. And what better way to celebrate it than to invite the Latino founder of a solution dedicated to the Latino population! In this episode, Alex Rochegude, Cofounder of Predictiv, invited Federico Von Son, CEO and Cofounder of SOMOS Ancestria, to discuss about how personalized medicine could be targeted to Latino populations. Latin America represents 25% of all the pharma industry revenue. However, the Latino population accounts for less than 1.2% of all genomic data used for drug discovery, and less than 1% in clinical trials. SOMOS is changing this by creating the world’s largest Latino population biobank, and providing high-resolution genomic services to the more than 650 million Latinos worldwide! --- Send in a voice message: https://podcasters.spotify.com/pod/show/thefutureofhealth/message

In this episode, Alex Rochegude, Cofounder of Predictiv, invited Michelle Colucci, Managing Partner and Founder of DigitalDX, to discuss about how technology is improving and changing our approach to diagnostics. DigitalDx Ventures is an early stage venture fund investing in A.I. and data enabled healthcare. DigitalDx has 7 portfolio companies focused on areas such as breast cancer, kidney health, mental health, Alzheimer's and brain health, lungs fluid, and women's health. The fund is located in Silicon Valley on the renowned Sand Hill road. --- Send in a voice message: https://podcasters.spotify.com/pod/show/thefutureofhealth/message

In this episode, Alex Rochegude, Cofounder of Predictiv, invited Ahmad Al-Hidiq, CEO and Cofounder of Kayan Health, to discuss about how telemedicine is changing our Healthcare System. Kayan Health is an enterprise Virtual Care Management solutions provider that delivers a suite of products which empower healthcare organizations, Governments and NGOs with innovative communications technologies and Artificially Intelligent solutions. --- Send in a voice message: https://podcasters.spotify.com/pod/show/thefutureofhealth/message

In this episode, Alex Rochegude, Cofounder of Predictiv, invited Adrien Chatillon to discuss about a new generation of medical treatments for Brain Diseases. Adrien is a serial entrepreneur, and the CEO and cofounder of Actipulse Neuroscience, a medical company specialized in Non-Invasive Brain Stimulation therapeutics for the treatment of Major Depressive Disorder, and that is also under clinical trials for Alzheimer's Disease and post-stroke rehabilitation. Actipulse Neuroscience has already treated more than 11,000 patients in the past two years for Major Depressive Disorders, and has an objective of reaching 100,000 patients by 2025. --- Send in a voice message: https://podcasters.spotify.com/pod/show/thefutureofhealth/message